These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23965899)

  • 21. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
    Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer.
    Wang J; Li J; Chen R; Yue H; Li W; Wu B; Bai Y; Zhu G; Lu X
    Clin Epigenetics; 2021 Oct; 13(1):190. PubMed ID: 34645493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
    Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
    Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
    [No Abstract]   [Full Text] [Related]  

  • 24. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
    Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
    Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
    Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
    Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
    Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
    Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
    Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
    Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
    Liu R; Hu R; Zeng Y; Zhang W; Zhou HH
    EBioMedicine; 2020 Jan; 51():102602. PubMed ID: 31911269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.